CAMBRIDGE, England – Owlstone Medical, a diagnostics company developing a breathalyzer for disease, is partnering with AstraZeneca to explore how breath can be used to identify biomarkers to help differentiate between disease phenotypes relevant for asthma and chronic obstructive pulmonary disease. Through the agreement, Owlstone Medical will provide AstraZeneca with access to its breath biopsy services, including the development of classification algorithms to identify breath biomarkers for precision medicine applications across asthma and COPD. “This agreement with AstraZeneca demonstrates our unrivalled expertise in breath biomarkers,” said Billy Boyle, co-founder and CEO of Owlstone Medical, in a statement. “Through our breath biopsy services we are well positioned to assist the AstraZeneca team to explore how breath biopsy can identify novel biomarkers for asthma and COPD and to optimize their application in precision medicine.”
SAN MATEO, Calif. – The U.S. Food and Drug Administration has cleared Adherium’s Smartinhale sensor for over-the-counter sales. The sensor was cleared for use in AstraZeneca’s Symbicort aerosol inhaler to monitor and promote asthma and COPD medication adherence as part of a self-management plan. It automatically records the date and time the inhaler is used and sends the information to an app on the user’s smartphone or tablet. “Over-the-counter sales of our Smartinhaler sensor for the Symbicort aerosol inhaler continues the advancement of our vision for stronger partnerships between patients and physicians by making adherence to personal management plans easier,” said Arik Anderson, CEO of Adherium, in a statement. “We are now well positioned to launch in the U.S., following successes in Europe and Australia.” OTC clearance means that Adherium’s Smartinhaler can now be sold directly to consumers, including through pharmacies and online, without the need for the patient to first obtain a prescription.
ATLANTA – A new collaborative initiative aims to use machine learning to better identify people living with chronic obstructive pulmonary disease who are at risk of exacerbations and hospitalization.
Health care technology company Jvion is collaborating with the COPD Foundation, the Geisinger health system and pharmaceutical company GSK to leverage cognitive machine technology and data for patients with COPD.
“The best way to prevent readmission is to prevent admission in the first place,” said Dr. Paul Simonelli, director of thoracic medicine at Geisinger. “This initiative will help us identify who is sick enough with COPD to be at risk of admission and how we can prevent it.”
The goal of the initiative is to use Jvion’s Cognitive Clinical Success Machine to identify COPD patients currently under the care of Geisinger who are at risk of hospitalization and most likely to benefit from new medications. The CCSM is an advanced artificial intelligence solution built using an Eigen Spheres engine that uses patient mapping to enable a comprehensive patient view that is amplified beyond the risk of an event to the clinical actions that will improve outcomes and drive patient engagement.
The initiative, funded by GSK, is divided into two phases: phase one will target COPD patients who have had an inpatient stay and who are at risk of a readmission within 30 days of their initial discharge; phase two will focus on identifying COPD patients at-risk of an avoidable hospitalization.
“This is a huge win for us,” said Craig Kephart, CEO of the COPD Foundation, who said the organization has had multiple requests over the years from health care providers looking for information on best practices to prevent readmissions and exacerbations, and preserve lung function for people with COPD. “Developing these algorithms will help to personalize treatment a little more.”
ATLANTA – Health care technology company Jvion is collaborating with the COPD Foundation, the Geisinger health system and health care company GSK to leverage cognitive machine technology and data for patients with chronic obstructive pulmonary disease.
The goal of the collaboration is to use Jvion’s Cognitive Clinical Success Machine to identify COPD patients who are currently under the care of Geisinger and who are at risk of hospitalization and most likely to benefit from new medications.
“By combining COPD disease expertise with the exceptional patient care delivered by Geisinger and Jvion’s leading Cognitive Clinical Success Machine, we are positioned to help patients across the nation,” said Craig Kephart, CEO of the COPD Foundation, in a statement. “This work is intended to demonstrate the power of leading edge, cognitive technology and patient care management to halt instances of rising risk and improve COPD patient lives.”
The Cognitive Clinical Success Machine is an advanced artificial intelligence solution built using Eigenspace—an approach that helps solve complex challenges such as quantum mechanics, search and consumer behavior, facial recognition and patient deterioration. It enables a comprehensive patient view that is amplified beyond the risk of an event to the clinical actions that will improve outcomes and drive patient engagement.
The project, funded by GSK, is divided into two phases. Phase one will target COPD patients who have had an inpatient stay and who are at risk of a readmission within 30 days of their initial discharge; phase two will focus on identifying COPD patients at-risk of an avoidable hospitalization.
“This work has the potential to revolutionize how we support COPD patients both inside and outside of the hospital,” said Dr. Paul Simonelli, director of thoracic medicine at Geisinger, in a statement. “We hope to demonstrate how innovation can improve quality, while lowering costs for vulnerable patient populations.”
MADISON, Wis. and ST. LOUIS – Propeller Health and Express Scripts have formed a strategic partnership to provide Propeller’s digital solution to Express Scripts members using inhaler sensors and a mobile app to manage asthma or COPD. Propeller’s digital sensors enable remote monitoring for patients enrolled in Express Scripts’ Pulmonary Care Value Program. “Our vision is to help patients with asthma or COPD understand and proactively manage their condition, allowing them to breathe easier day in and day out,” said Dr. Glen Stettin, senior vice president and chief innovation officer at Express Scripts, in a statement. Using Bluetooth technology, a Propeller digital sensor is attached to a patient’s inhaler and synced to his or her smartphone. The inhaler’s activity trends are reviewed by pulmonary pharmacists within Express Scripts’ Pulmonary Therapeutic Resource Center, and when the Pulmonary TRC sees that a patient is overusing their rescue inhaler or is non-adherent with their controller medication, pulmonary pharmacists engage and perform counseling using patient-specific data. Through the Propeller mobile app, patients with asthma or COPD also can track their symptoms and triggers, monitor daily asthma condition forecasts and receive tips to encourage more effective self-management.
BOONE, N.C. – Early clinical studies have shown that a fully digital, soft mist inhaler developed by Pneuma Respiratory can effectively deliver a number of different types of medicines to the lungs. “More than 40 million people suffer from asthma or COPD in the U.S.,” said James Bauler, director of business development at Pneuma Respiratory. “It’s well documented that patients have problems adopting the correct inhaler technique and thus receiving the expected dose of medication both with dry powder and existing metered-dose inhalers. With a proven team of technology and health care leaders, Pneuma expects to make significant gains in pulmonary drug delivery.” The device uses electronic breath actuation and a soft mist ejector. As a patient inhales, the ejector senses the breath and activates automatically. This allows the medication droplets to ride into the lungs on the patients’ breath, without propellants. Paired with a mobile app, the device is capable of delivering real-time dose verification data. Two clinical studies with COPD patients using small-molecule asthma and COPD medications validated the platform using bronchodilation as the outcome. A feature of the device is its ability to deliver different sized droplets of medicine via its droplet ejector technology, which allows the device to potentially target different areas of the lungs, said Bauler.
LOUISVILLE, Ky. – Digital therapeutics company Revon Systems is partnering with Humana on a pilot for a select population of Medicare Advantage members diagnosed with chronic obstructive pulmonary disease. “We are pleased to work with Humana on their Bold Goal to reduce chronic disease by 20% by 2020,” said Ted Smith, CEO of Revon Systems, in a statement. “We know that COPD can be a challenge for patients to manage, and we hope that Revon’s Smart Symptom Tracker technology will result in more Healthy Days for the participating members.” The pilot will use Revon’s Smart Symptom Tracker mobile app and the free Breathe COPD Resource Kit, which contains a pulse oximeter and thermometer. The app features a self-triage function intended to guide members toward the right level of care. The program seeks to evaluate the impact of digital therapies on clinical and business outcomes.
‘mHealth is a huge opportunity for us to be as close to the patient as possible’
ATLANTA – Mobile telehealth and remote patient monitoring company SynsorMed is seeking strategic partnerships to reach patients with chronic obstructive pulmonary disease.
The company recently announced a partnership with oxygen delivery equipment manufacturer CAIRE Inc. that created “CAIREview powered by SynsorMed,” a mobile solution to monitor patient conditions outside of the hospital by connecting a patient’s oxygen concentrator to a customized dashboard and mobile app.
“We’re right there in that key space,” said Theo Harvey, co-founder of SynsorMed. “mHealth technology is a huge opportunity for us to be as close to the patient as possible.”
SynsorMed’s platform encourages patient engagement and compliance by combining telehealth, remote patient monitoring and machine learning. A mobile app connects to health monitoring devices in the home, collecting and analyzing data to give a complete picture of a patient’s health status.
SynsorMed is also seeking partnerships with health systems and clinicians, and is considering integrating a voice-enabled notification engine to its platform.
“In health care, it can seem like you’re going back in time when it comes to technology,” he said. “There was some initial hesitation by providers as telehealth solutions were just taking off, but we’re starting to see a shift as the newness is wearing off and mobile devices are becoming ubiquitous.”
MONTREAL – Tactio Health Group has teamed up with Medical International Research for a telehealth solution designed specifically to monitor COPD patients remotely. The solution adds Bluetooth-enabled MIR spirometers that integrate with TactioPM patient apps. “With MIR SmartOne, COPD patients being monitored remotely with TactioRPM systems can benefit from an easy and simple way to self-test, report and exchange with their pneumologist,” said Michel Nadeau, CEO of Tactio, in a statement. MIR SmartOne is a portable FEV1 and Peak Flow meter enabling simple personal self-tracking of lung health with clinical accuracy. Tactio RPM is an app-enabled platform that combines mobile apps, connected health integrations, patient questionnaires and digital coaching programs.
MADISON, Wis. –Propeller Health has extended its collaboration with respiratory medicine provider GSK.
The two companies began working together in 2015 to research and collect evidence from Propeller’s clip-on sensor and software platform used in conjunction with GSK’s ELLIPTA inhaler and respiratory medicines for asthma and COPD.
“We are excited to be working closely with GSK to make the sensor for the ELLIPTA inhaler available in our commercial programs, and for the first time, as part of commercial pilots with GSK outside the U.S.,” said David Van Sickle, CEO and co-founder of Propeller, in a statement.
The clip-on sensor for the ELLIPTA Inhaler automatically records medication use, which the Propeller platform analyzes and presents to patients and physicians through its data-driven digital interfaces, providing an in-depth view into adherence.
The Propeller sensor and software program for the ELLIPTA Inhaler received CE marking and clearance from the U.S. Food and Drug Administration last year.
“Digital innovations, like sensor technologies, will help us ensure patients receive the best possible package of care management and treatment for their respiratory condition,” said Eric Dube, senior vice president and head of GSK, in a statement.